REGENERON PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
REGENERON PHARMACEUTICALS, INC. (REGN) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$47.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$47.70M, a 303.85% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$65.60M, a 277.30% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $16.50M, a 87.32% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was $23.40M, a 220.55% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $85.40M, a 16.99% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $73.00M, a 53.77% decline from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $157.90M.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$212.60M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$47.70M 10-Q · filed 2026-07-30 | -$113.30M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2026-03-31 | -$65.60M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $85.40M 10-K · filed 2026-02-04 | |||
| 2025-09-30 | $16.50M 10-Q · filed 2025-10-28 | $39.90M derived: sum of 2 quarters · filed 2026-07-30 | $76.90M derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $23.40M 10-Q · filed 2026-07-30 | $60.40M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $37.00M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $73.00M 10-K · filed 2026-02-04 | |||
| 2024-09-30 | $130.10M 10-Q · filed 2025-10-28 | $137.40M derived: sum of 2 quarters · filed 2025-10-28 | $141.10M derived: sum of 3 quarters · filed 2025-10-28 | |
| 2024-06-30 | $7.30M 10-Q · filed 2025-10-28 | $11.00M derived: sum of 2 quarters · filed 2025-10-28 | ||
| 2024-03-31 | $3.70M 10-Q · filed 2025-10-28 | |||
| 2023-12-31 | $157.90M 10-K · filed 2026-02-04 | |||
| 2023-09-30 | $20.90M 10-Q · filed 2024-10-31 | $4.80M derived: sum of 2 quarters · filed 2024-10-31 | $62.00M derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | -$16.10M 10-Q · filed 2024-10-31 | $41.10M derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $57.20M 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | -$212.60M 10-K · filed 2025-02-05 | |||
| 2020-12-31 | $8.20M 10-K · filed 2021-02-08 | |||
| 2019-12-31 | $33.40M 10-K · filed 2021-02-08 | |||
| 2018-12-31 | -$6.30M 10-K · filed 2021-02-08 | |||
| 2017-12-31 | $13.40M 10-K · filed 2020-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |